Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

9B7B

Crystal structure of humanized 44H10 Fab Version 22 in complex with HLA-DR (HLA-DRA*01:01/HLA-DRB1*04:01)

Summary for 9B7B
Entry DOI10.2210/pdb9b7b/pdb
DescriptorHLA class II histocompatibility antigen, DR alpha chain, Hemagglutinin HA1 chain, HLA class II histocompatibility antigen DR beta chain, h44H10-V22 Antibody, heavy chain, ... (6 entities in total)
Functional Keywordsantibody, humanized, mhc class ii, immune system
Biological sourceHomo sapiens (human)
More
Total number of polymer chains8
Total formula weight191261.77
Authors
Kassardjian, A.,Julien, J.P. (deposition date: 2024-03-27, release date: 2024-08-07, Last modification date: 2024-10-30)
Primary citationKassardjian, A.,Ivanochko, D.,Barber, B.,Jetha, A.,Julien, J.P.
Humanization of Pan-HLA-DR mAb 44H10 Hinges on Critical Residues in the Antibody Framework.
Antibodies, 13:-, 2024
Cited by
PubMed Abstract: Reducing the immunogenicity of animal-derived monoclonal antibodies (mAbs) for use in humans is critical to maximize therapeutic effectiveness and preclude potential adverse events. While traditional humanization methods have primarily focused on grafting antibody Complementarity-Determining Regions (CDRs) on homologous human antibody scaffolds, framework regions can also play essential roles in antigen binding. Here, we describe the humanization of the pan-HLA-DR mAb 44H10, a murine antibody displaying significant involvement of the framework region in antigen binding. Using a structure-guided approach, we identify and restore framework residues that directly interact with the antigen or indirectly modulate antigen binding by shaping the antibody paratope and engineer a humanized antibody with affinity, biophysical profile, and molecular binding basis comparable to that of the parental 44H10 mAb. As a humanized molecule, this antibody holds promise as a scaffold for the development of MHC class II-targeting therapeutics and vaccines.
PubMed: 39051333
DOI: 10.3390/antib13030057
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3.08 Å)
Structure validation

227561

PDB entries from 2024-11-20

PDB statisticsPDBj update infoContact PDBjnumon